therapy
-
SOM3355 Moves Toward Phase 3 as Both EMA and FDA Signal Support
SOM3355, a drug to help manage HD symptoms, has received a positive opinion from the EMA for orphan drug designation, and the company is aligned with the FDA after its End-of-Phase-2 meeting. A global Phase 3 trial is expected to start in 2026.
-
Tooth fairy therapy? Stem cells from teeth tested in a small Huntington’s disease trial
A trial tested stem cells from human teeth as a possible treatment for HD. The approach appeared safe with some improvements in symptoms, but the small size of the study and the unclear underlying science of this approach means caution is urged.
-
2025 HDBuzz Prize: ACTing on HD: Exploring Acceptance and Commitment Therapy to Improve Mental Health in People with Huntington’s Disease and Their Caregiver
We’re proud to announce Nicolo Zarotti as a 2025 HDBuzz Prize winner! A new case study shows Acceptance & Commitment Therapy (ACT) can improve mood and boost quality of life for people with HD, and help caregivers too.